One of the characteristics of the anatomical lesion observed in juvenile chronic arthritis (JCA) is an infiltration of inflammatory cells. The chemotaxis of polymorphonuclear and mononuclear cells towards the inflammatory site is considered to be an important mechanism leading to the formation of the lesion.1 Mowat and Baum have found, using the Boyden chamber's system, that the polymorphonuclear (PMN) leucocytes from 8 children with JCA have a significant decrease ofchemotaxis.2 3It was suggested that this impairment was due to phagocytosis of immune complexes by the patient's leucocytes.
Our object was to study chemotactic activity in a group of 21 children with JCA using a direct microscopic observation method,45 which allowed us to evaluate 3 different parameters: (1) the chemotaxis of the PMN leucocytes; (2) the chemotactic factors generated in the patients' serum in the presence of immune complexes; (3) the effect of the patients' or normal serum on the chemotactic response of normal PMN leucocytes previously incubated in the tested serum. We found that the chemotaxis of patient PMN and the generation of chemotactic substances in the patient's sera in the presence of immune complexes were comparable to that of the controls. However, the patient's sera enhanced the chemotactic response of normal PMN after a previous incubation with abnormal sera, suggesting the presence of an enhancing factor of leucochemotaxis in JCA sera. significant difference between the ages of the patients with JCA and the patients in the control group (respectively 1I 09 + 3 37 and 10 60 ± 7 43; Student's t test, P=0*27). Three children with systemic lupus erythematosus (SLE) were also investigated, 2 of them being under steroid therapy, the other before he had received treatment.
Chemotaxis assay. Each patient was investigated in comparison with a normal control. 5 ml of blood was withdrawn in a sterile syringe with 50 IU of preservative-free heparin (Liquemine) and was allowed to sediment in a plastic tube at room temperature for about 30 group.bmj.com on June 27, 2017 -Published by http://ard.bmj.com/ Downloaded from (col. 3) to chemotactic factor generated by normal human serum in the presence of BSA-aBSA were identical to responses of normal leucocytes studied in the same condition (col. 1). Generation of chemotactic factors by JCA patients' sera activated by BSA-aBSA (col. 2) did not differ from the chemotactic activity obtained with normal human sera. However, while the preincubation of normal leucocytes in the presence of normal human serum (col. 4) and noninflammatory sera (col. 5) had no effect, the preincubation of normal leucocytes in 19 out of 21 JCA patients' sera (col. 6) significantly enhanced their chemotactic responses to chemotactic factor generated by normal human serum activated by BSA-aBSA complexes (P<0 001). Incubation of normal leucocytes in SLE sera did not affect their chemotactic responses (col. 9) .
Chemotactic enhancing factors appeared to be not dialysable and resistant at 560C, but their effect was abolished by heating to 800C. Storage of patients' sera at -700C did not modify their enhancing effect. The effect was not present in ammonium sulphate precipitated fractions (PF) and recovered in supernatants (SF) (cols. 7 and 8). Elimination of the majority of albumin in SF by a goat antihuman albumin antiserum abolished the chemotactic enhancing activity. A possible enhancing chemotactic effect of albumin itself was eliminated, since chemotactic experiments performed with normal human or bovine albumin and ovalbumin did not modify the leucochemotaxis.
Discussion
In the present study we observed that the large majority of JCA patients' leucocytes responded normally to chemotactic factors, in contrast to previous studies performed in 8 JCA patients by Mowat et al. 2 3 We showed that the generation of chemotactic factors was identical in serum obtained from JCA patients and normal human serum activated by immune complexes. However, incubation of normal leucocytes in the presence of JCA serum resulted in a significant increase of their chemotactic responses. This finding suggests that JCA serum contains chemotactic enhancing factors (CEF) not present in normal serum, in sera from 21 patients with noninflammatory diseases, and in sera from 3 SLE patients.
In an attempt to characterise CEF present in JCA sera we found that the activity was not dialysable and not detected in ammonium sulphate precipitate but was recovered in supernatant. This result indicates that the effect was not due to antibodies or immune complexes. The enhancing activity was not due either to complement derivative such as C3a or CSa, since these components with molecular weights of 72007 and 85008 are dialysable. The fact that CEF activity was abolished by precipitation of albumin fraction suggested that CEF was associated with albumin. Albumin fraction from normal human serum or from other species did not exert a chemotactic enhancing effect. Thus it is likely that CEF may be bound to albumin fractions.
Chemotactic enhancing factor (CEF) was detected in the majority of JCA patients tested in the present study. This activity could not be related to the various clinical aspects of the disease, since it was observed both in systemic onset cases and in cases of polyarticular or pauciarticular onset. Similarly, we did not find any correlation with the presence of acute-phase reactants, which more or less varied in intensity from one patient to another. Therapeutic agents (gold salts, salicylate, and corticosteroids) did not seem to affect the chemotactic enhancing activity. However, in 1 patient who received chlorambucil at the time of the study'no CEF was found. Hyperleucocytosis, with high rate of PMN, raised the question of a possible role of this serum CEF on the appearance of the hyperleucocytosis. The mechanism by which this enhancing capacity is generated and the role of this factor in the inflammatory process remain a matter of speculation. Two hypotheses may be suggested-increased production of the CEF itself or dysregulation of the chemotactic factor inactivator usually found in normal human serum.°10
